The National Medical Products Administration of China (NMPA) has approved CanSino Biologics’ (CanSinoBIO) recombinant Covid-19 vaccine (Adenovirus Type 5 Vector) for inhalation, Convidecia Air, as a booster.
This vaccine leverages the same adenovirus vector technological platform as Convidecia, the intramuscular version.
Providing a non-invasive option, Convidecia Air utilises a nebuliser to convert liquid into an aerosol for inhaling through the mouth, the company noted.
The needle-free vaccine can also elicit complete immune protection against the SARS-CoV-2 virus after just a single inhalation.
In March last year, CanSinoBIO obtained approval for the clinical trial application to analyse Convidecia Air.
CNBC reported in April last year that the vaccine is being developed by the company in partnership with the Beijing Institute of Biotechnology (BIB).
According to studies, Convidecia Air could prompt robust cellular, humoral and mucosal immunity to attain triple protection as well as control the virus spread and the infection.
The company has presently attained steady manufacturing of several innovative vaccines and set up a supply chain worldwide to increase accessibility to quality vaccine products for people globally.
In May, CanSinoBIO received an emergency use listing (EUL) from the World Health Organization (WHO) for its recombinant Covid-19 shot, Convidecia.
Administered as a single dose, the genetically engineered vaccine has the replication-defective adenovirus type 5 vector that expresses the spike S protein of the SARS-CoV-2 virus.
The WHO decision is based on the totality of scientific findings submitted by the company, including data from a Phase III clinical trial which evaluated the safety and efficacy of this shot.